利奈唑胺治疗革兰氏阳性菌导管相关性菌血症的临床评价  

A clinical study of Linezolid in treatment of catheter-associated bloodstream infections by gram-positive bacteria

作　　者：李超梁[1] 

机构地区：[1]广东省江门市中心医院重症医学科,江门529030

出　　处：《江西医药》2014年第6期482-485,共4页Jiangxi Medical Journal

摘　　要：目的评估利奈唑胺治疗革兰氏阳性菌导管相关性菌血症的疗效和安全性。方法以2009年1月-2013年10月在我院重症医学科住院、确诊为革兰氏阳性菌导管相关性菌血症的患者为研究对象,随机分成两组(利奈唑胺组和万古霉素组),分别予利奈唑胺注射液600mg或万古霉素注射液1.0g静脉滴注,每12h 1次,连用14d,比较两种药物的临床疗效及不良反应。结果利奈唑胺组退热时间较万古霉素组短(P<0.05);两组痊愈率、有效率、细菌清除率无统计学差异(P>0.05);治疗前后两组的白细胞计数、中性粒细胞比例、C-反应蛋白、降钙素原均下降,但两组比较无显著性差异(P>0.05);利奈唑胺不良反应少于万古霉素(P<0.05)。结论利奈唑胺治疗革兰氏阳性菌导管相关性菌血症疗效显著,安全性好。Objective To evaluate the efficacy and safety of Linezolid in treatment of catheter-associated bloodstream infec-tions by gram-positive bacteria. Methods Patients diagnosed catheter-associated bloodstream infections by gram-positive bacteria between January 2009 and October 2013 were collected and allocated to receive one of two drugs,Linezolid 1200mg/day or van-comycin 2000mg/day given in two divided doses for 14 days. Clinical efficacy and adverse reactions were compared. Results Fever clearance time of Linezolid was shorter than that of Vancomycin（P〈0.05）;There were no significant differences in the clinic cure rates,clinical efficacy rates and the bacterial clearance rates between the two groups （P〉0.05）;after treatment white blood cell count,neutrophil ratio,C-reactive protein,calcitonin all declined,but there were no significant differences between the two groups （P〉0.05）;adverse reactions of Linezolid were lower than that of Vancomycin （P〈0.05）. Conclusion Linezolid has an ex-cellent clinical efficacy and good safety proflie in treating patients with catheter-associated bloodstream infections by gram-posi-tive bacteria.

关 键 词：利奈唑胺 万古霉素 革兰氏阳性菌 导管相关性菌血症 安全性 

分 类 号：R197.3[医药卫生—卫生事业管理]